CRITICAL PATH INSTITUTE

Curates, standardizes, and integrates individual patient records and clinical trial data into various databases and platforms, including for Alzheimer’s, Duchenne Muscular Dystrophy, Parkinson’s, Multiple Sclerosis, Polycystic Kidney Disease, and tuberculosis, to enable research and analysis.

Develops disease progression models and clinical trial simulation tools for various conditions, including Progressive Supranuclear Palsy, Friedreich’s Ataxia, Alzheimer’s disease, Duchenne Muscular Dystrophy, and Parkinson’s Disease, often receiving regulatory endorsement.

Develops disease progression models and clinical trial simulation tools for various conditions, such as Progressive Supranuclear Palsy, Friedreich’s Ataxia, Duchenne Muscular Dystrophy, and Parkinson’s Disease, often using clinical trial and natural history data.

Develops and secures regulatory endorsement for viable biomarkers for various diseases, including Alzheimer’s, Parkinson’s, type 1 diabetes, kidney disease, and tuberculosis, and for detecting drug-induced pancreatic injury.

Develops and validates biomarkers for various diseases, including the first imaging biomarker for polycystic kidney disease, and secures regulatory endorsement for biomarkers in Alzheimer’s, Parkinson’s, type 1 diabetes, kidney disease, tuberculosis, and drug-induced pancreatic injury.

Operates the RDCA-DAP® platform and other disease-specific databases to standardize, integrate, and enable analytics on rare disease data, supporting biomarker development, trial design, and regulatory decision-making. Hosts over 100 datasets across rare diseases and maintains similar platforms for tuberculosis, Alzheimer’s, Parkinson’s, Duchenne Muscular Dystrophy, and polycystic kidney disease.

Creates and validates biomarkers, clinical trial simulation tools, and clinical outcome assessments that have received formal regulatory support from the FDA and EMA. The organization has achieved more global regulatory endorsements for such tools than any other since 2008.

Establishes and maintains integrated data and analytics platforms and databases for various diseases, including rare diseases (RDCA-DAP), Alzheimer’s, Duchenne Muscular Dystrophy, Parkinson’s, Multiple Sclerosis, Polycystic Kidney Disease, and Tuberculosis (TB-APEX, TB-PACTS, PAN-TB), standardizing and integrating patient records and study data for public access or qualified researchers.

Operates the RDCA-DAP® platform, which hosts over 100 datasets across various rare diseases, to integrate and standardize rare disease data, enabling analytics for understanding disease progression, biomarker development, and innovative trial design.

Achieved more global regulatory endorsements for drug development tools than any other organization since 2008, including qualification opinions from the EMA for the iBox Scoring System and pancreatic islet autoantibodies.

Convenes global stakeholders, including regulatory agencies, biopharmaceutical firms, universities, and patient groups, to develop tools and processes that accelerate medical product development and regulatory decision-making.

Leads work packages and supports communication for establishing processes and infrastructure for secure sharing of standardized data in international projects like Unite4TB and ERA4TB, and makes preclinical study data available through its Data Archive platform.

Convenes global stakeholders to develop tools and processes that accelerate medical product development and regulatory decision-making, and supports communication and training for efficient use of real-world data in Europe.

Leads work packages in projects like Unite4TB and ERA4TB to establish processes and infrastructure for secure sharing of standardized data and images in tuberculosis research.

Convenes stakeholders from academia, industry, regulatory agencies, and patient advocacy groups to manage large-scale research initiatives that accelerate medical product development and regulatory decision-making.

Manages large-scale collaborative research programs involving stakeholders from academia, industry, patient advocacy groups, and regulatory agencies to accelerate drug development, particularly for rare and orphan diseases.

Manages large-scale collaborative research programs involving diverse stakeholders from academia, industry, patient advocacy groups, and regulatory agencies to accelerate drug development, particularly for rare diseases.

Establishes initiatives, such as the Critical Path for Alpha-1 Antitrypsin Deficiency, and hosts conferences to advance research collaboration and data harmonization for specific diseases, including rare and orphan diseases.

Established the Critical Path for Alpha-1 Antitrypsin Deficiency in 2023 to accelerate medical progress for individuals with AATD.

Hosted its first conference on Rare and Orphan Diseases in September 2023 to advance research collaboration and data harmonization.

Organized the first conference on Rare and Orphan Diseases in September 2023 to promote research collaboration and data harmonization across the rare disease community.

Contributed to process improvements that enabled the development of the first new tuberculosis treatment and regimen in over 50 years.

Develops clinical outcome assessments that incorporate the patient’s voice to evaluate treatment efficacy for conditions such as asthma, depression, irritable bowel syndrome, myelofibrosis, and non-small cell lung cancer.

Develops clinical outcome assessments that incorporate patient perspectives to evaluate treatment efficacy for conditions such as asthma, depression, irritable bowel syndrome, myelofibrosis, and non-small cell lung cancer.

Supports infrastructure development, secure data sharing, and training programs in Europe and global tuberculosis consortia to advance the use of real-world data in regulatory science and drug development.